AstraZeneca India and Telangana Government Forge Partnership for AI-Powered Lung Cancer Screening
In a significant move to combat the rising burden of lung cancer, AstraZeneca Pharma India, a subsidiary of the British-Swedish pharmaceutical giant AstraZeneca Plc, has signed a memorandum of understanding (MoU) with the Telangana government. This collaboration aims to introduce artificial intelligence (AI)-powered lung cancer screening across 20 public health facilities in the state, targeting both urban and rural populations to enhance early detection efforts.
Deploying Advanced AI Technology for Early Diagnosis
As part of this initiative, the screening program will utilize an AI-enabled chest X-ray solution developed by Indian startup Qure.ai. This technology is designed to assist clinicians in identifying high-risk pulmonary nodules, which are key precursors to lung cancer, along with 29 other lung conditions. Patients flagged as high-risk through this AI system will be promptly referred for confirmation tests or follow-up care, streamlining the diagnostic process and potentially saving lives.
Addressing the Growing Lung Cancer Crisis in India
The launch of this program comes at a critical time, as lung cancer cases in India have been steadily increasing. Data shows a rise from approximately 63,700 cases in 2015 to over 81,200 projected for 2025. Alarmingly, about 80% to 85% of patients are diagnosed at advanced stages, contributing to nearly 60,000 deaths annually. Telangana, in particular, faces a significant cancer burden, with 46,762 new adult cancer cases projected for 2026, where women are expected to account for a larger share than men.
Official Statements Highlight the Importance of Technology and Training
Telangana Health Commissioner Dr. S. Sangeetha Satyanarayana emphasized that this partnership will help tackle the issue of late diagnosis by integrating cutting-edge technology into the public healthcare system. She noted that early intervention is crucial for improving patient outcomes and reducing mortality rates. Meanwhile, AstraZeneca India Country President Praveen Rao Akkinepally underscored the critical role of early detection in enhancing treatment success. He added that the rollout of the program will include comprehensive training for healthcare workers and infrastructure support to ensure long-term implementation and sustainability.
Key Features of the AI Screening Initiative
- Wide Reach: The screening will be deployed across 20 public health facilities, ensuring accessibility in diverse settings.
- Advanced Detection: Qure.ai's AI solution can identify high-risk pulmonary nodules and 29 other lung conditions with high accuracy.
- Referral System: High-risk patients will be directed to confirmation tests or follow-up care, facilitating timely medical intervention.
- Training and Support: The program includes training for healthcare professionals and infrastructure enhancements to support ongoing operations.
This initiative represents a proactive step towards leveraging technology to address public health challenges, with the potential to significantly impact lung cancer management in Telangana and serve as a model for other regions in India.
